Clinical Trial Update: An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of BIBF 1120 (nintedanib) in patients with relapsed or refractory multiple myeloma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BIBF 1120 (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED